Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Phillip S Pang

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Journal of Gastroenterology and Hepatology|February 5, 2016
Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virusWan-Long Chuang, Rong-Nan Chien, Cheng-Yuan Peng, et al.
Cell Reports. Medicine|August 17, 2022
Antibody therapy reverses biological signatures of COVID-19 progressionM Cyrus Maher, Leah B Soriaga, Anil Gupta, et al.
The New England Journal of Medicine|April 15, 2014
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infectionNezam Afdhal, Stefan Zeuzem, Paul Kwo, et al.
Journal of Hepatology|June 8, 2023
Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: Results from randomized clinical trialsEd Gane, Young-Suk Lim, Jae B Kim, et al.
Hepatology International|May 21, 2016
A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virusYoung-Suk Lim, Sang Hoon Ahn, Kwan Sik Lee, et al.
The Lancet. Infectious Diseases|February 25, 2016
Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trialMichael Manns, Didier Samuel, Edward J Gane, et al.
The Lancet. Infectious Diseases|April 13, 2015
Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trialMasashi Mizokami, Osamu Yokosuka, Tetsuo Takehara, et al.
The Lancet. Infectious Diseases|March 17, 2015
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)Marc Bourlière, Jean-Pierre Bronowicki, Victor de Ledinghen, et al.
JAMA|February 24, 2015
Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infectionAnu Osinusi, Kerry Townsend, Anita Kohli, et al.
The New England Journal of Medicine|April 15, 2014
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infectionNezam Afdhal, K Rajender Reddy, David R Nelson, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Journal of Gastroenterology and Hepatology|February 5, 2016
Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virusWan-Long Chuang, Rong-Nan Chien, Cheng-Yuan Peng, et al.
Cell Reports. Medicine|August 17, 2022
Antibody therapy reverses biological signatures of COVID-19 progressionM Cyrus Maher, Leah B Soriaga, Anil Gupta, et al.
The New England Journal of Medicine|April 15, 2014
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infectionNezam Afdhal, Stefan Zeuzem, Paul Kwo, et al.
Journal of Hepatology|June 8, 2023
Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: Results from randomized clinical trialsEd Gane, Young-Suk Lim, Jae B Kim, et al.
Hepatology International|May 21, 2016
A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virusYoung-Suk Lim, Sang Hoon Ahn, Kwan Sik Lee, et al.
The Lancet. Infectious Diseases|February 25, 2016
Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trialMichael Manns, Didier Samuel, Edward J Gane, et al.
The Lancet. Infectious Diseases|April 13, 2015
Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trialMasashi Mizokami, Osamu Yokosuka, Tetsuo Takehara, et al.
The Lancet. Infectious Diseases|March 17, 2015
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)Marc Bourlière, Jean-Pierre Bronowicki, Victor de Ledinghen, et al.
JAMA|February 24, 2015
Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infectionAnu Osinusi, Kerry Townsend, Anita Kohli, et al.
The New England Journal of Medicine|April 15, 2014
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infectionNezam Afdhal, K Rajender Reddy, David R Nelson, et al.
Pageof 5